Advanced-stage hepatocellular carcinoma is currently treated with various anti-PD-(L)1 antibody-containing regimens. Now, a triplet combining the anti-TIGIT antibody tiragolumab with one of these ...

The Islamabad High Court (IHC) has suspended a cabinet sub-committee's decision to place names of the family members of a petitioner, Usman Khan, on the Exit Control List (ECL). The court has ...

Department of Anatomy and Cell Biology, School of Medicine and Health Sciences, George Washington University, Washington, DC, United States Thomas Jefferson High School for Science and Technology, ...

For patients at metastatic stage IV, besides personalized mutations, an additional panel of approximately 500 hotspot mutations ... circulating tumor DNA; DCIS, ductal carcinoma in situ; ER, estrogen ...

Adrenal cortical cancer (ACC) is very rare and also known as adrenocortical carcinoma. ACC starts in the outer layer of the adrenal glands, which are next to the kidneys. The adrenal glands are small ...

The OpenWallet Forum High Level Panel meeting is an annual event. Its main objectives are to align stakeholders on critical questions such as consumer choice, inclusion and ensure ongoing support and ...

This study investigates the biomechanical changes induced by cell crowding, focusing on pro-invasive cell volume reduction in ductal carcinoma in situ (DCIS). Crowding specifically enhanced ...

IHC panel for a retroperitoneal small round cell tumour in adults. Occurrence, of B-LBL in the pancreas and kidneys which are an extremely unusual site, clinically mimicking acute pancreatitis and ...

It’s less advanced than stage I cancer. There are two types of stage 0 breast cancer: If you’re diagnosed with DCIS, your pathology report will come with a grade. Nuclear grade 3 is the most ...

Search for other works by this author on: When the problem of carcinoma is approached from the metabolic aspect, the first question which arises is: how does the metabolism of growing tissue differ ...

International Holding Company (IHC) has reported significant growth in its full-year 2024 financial results, underscoring its ability to drive strong performance and strategic portfolio management.

Jeff Auletta, MD, discusses his key takeaways from the 2025 Transplant and Cellular Therapy Meetings. Jeff Auletta, MD, senior vice president of health equity at the National Marrow Donor Program and ...